4-Year Follow-Up after Transatrial Transcatheter Tricuspid Valve Replacement with the LuX-Valve.

ABSTRACT: Tricuspid regurgitation (TR) has become one of the most common valve diseases. Patients with severe TR are often at high surgical mortality risk. Transcatheter tricuspid valve interventions have emerged as a promising alternative to open-heart surgery. The LuX-Valve is a novel radial force-independent transcatheter tricuspid valve replacement system. We presented here the first patient treated for symptomatic TR using the LuX-Valve replacement system in September 2018. Four-year follow-up outcomes suggested that the bioprosthesis was in normal function, with stable hemodynamics (mean transtricuspid gradient 2.55 mmHg) and the patient's clinical symptoms were significantly improved; thus indicating that it is a safe, effective, and satisfactory case of the LuX-Valve application in treating

SUBMITTER: Ning X 

PROVIDER: S-EPMC9783009 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature